All the information on this page is sourced for Thomson Reuters Cortellis for Competitive Intelligence TM, find out more about Cortellis for Competitive Intelligence and take a free two week trial to see what Cortellis for Competitive Intelligence can do for you.
Content last updated January 27, 2012.
Etanercept (Enbrel) is a fusion protein comprising the extracellular domain of human p75 TNF receptor linked to the Fc portion of human IgG1and just one of the many drugs covered in Thomson Reuters Cortellis for Competitive Intelligence.In the Drug Report below you will see the drug overview information, news, deals, development status, literature evaluations, SWOT analysis, patent position and sales and market share data, all of which is shown in Cortellis for Competitive Intelligence, in fact there are over 40,000 of these Drug Reports in Cortellis for Competitive Intelligence.
Cortellis for Competitive Intelligence combines the same premier information used by the world's leading pharmaceutical companies from products such as Thomson Reuters Pharma TM and Thomson Reuters Partnering TM (formerly IDDB). Featuring daily updates and timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.
All Cortellis for Competitive Intelligence content is subject to an exhaustive editorial review process conducted by scientists, Pharma professionals, regulatory experts, and generics specialists. It is also updated regularly, so you get the most accurate and up-to-date information on the pharmaceutical data that matters to you.
Take a two week trial of Cortellis for Competitive Intelligence and see what it can do for you.
|Company||Immunex Corp (Amgen Inc)|
|Highest dev status||Launched|
|Therapy areas||Endometriosis; Hepatitis C virus infection; HIV infection; Psoriatic arthritis; Hidradenitis; Myositis; Psoriasis; Rheumatoid arthritis; Juvenile rheumatoid arthritis; Asthma; Bone marrow failure; Idiopathic pulmonary fibrosis; Ankylosing spondylitis; Cardiac failure; Graft versus host disease; Cancer; Malnutrition; Kawasaki disease; Crohns disease|
|Actions||Systemic antipsoriatic product; Anticancer; Cardioprotectant; Anti-inflammatory; Immunosuppressant; TNF antagonist; Fibrosuppressant; TNF binding agent; Type II TNF receptor modulator; Antiviral|
|Technologies||DNA technology; Cell culture; Subcutaneous formulation; Freeze drying; Biological therapeutic; Protein fusion; Liquid formulation|
|Target||TNF receptor;Type II TNF receptor|
|Reason for update||Sales and market share updated, 8 references added [1257949, 1257983, 1258008, 1258010, 1258014, 1258015, 1258067, 1258290]|